<SEC-DOCUMENT>0000932471-25-000174.txt : 20250130
<SEC-HEADER>0000932471-25-000174.hdr.sgml : 20250130
<ACCEPTANCE-DATETIME>20250130215802
ACCESSION NUMBER:		0000932471-25-000174
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250130

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-60487
		FILM NUMBER:		25575651

	BUSINESS ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VANGUARD GROUP INC
		CENTRAL INDEX KEY:			0000102909
		ORGANIZATION NAME:           	
		IRS NUMBER:				231945930
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		100 VANGUARD BLVD
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		6106691000

	MAIL ADDRESS:	
		STREET 1:		PO BOX 2600
		STREET 2:		V26
		CITY:			VALLEY FORGE
		STATE:			PA
		ZIP:			19482-2600
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001104659-20-016487</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0000102909</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>5</amendmentNo>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001055726</issuerCik>
<issuerName>Inovio Pharmaceuticals Inc</issuerName>
<issuerCusip>45773H409</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>660 West Germantown Pike Suite 110</com:street1>
<com:city>Plymouth Meeting</com:city>
<com:stateOrCountry>PA</com:stateOrCountry>
<com:zipCode>19462</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>
<reportingPersonName>The Vanguard Group</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>PA</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>11309</sharedVotingPower>
<soleDispositivePower>1654699</soleDispositivePower>
<sharedDispositivePower>18888</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1673587</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<classPercent>4.64</classPercent>
<typeOfReportingPerson>IA</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Inovio Pharmaceuticals Inc</issuerName>
<issuerPrincipalExecutiveOfficeAddress>660 West Germantown Pike Suite 110, Plymouth Meeting, PA, 19462</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>The Vanguard Group</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>100 Vanguard Blvd., Malvern, PA 19355</principalBusinessOfficeOrResidenceAddress>
<citizenship>PA</citizenship>
</item2>
<item3>
<notApplicableFlag>N</notApplicableFlag>
<typeOfPersonFiling>IA</typeOfPersonFiling>
</item3>
<item4>
<amountBeneficiallyOwned>1673587</amountBeneficiallyOwned>
<classPercent>4.64</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>0</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>11309</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>1654699</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>18888</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>N</notApplicableFlag>
<classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
</item5>
<item6>
<notApplicableFlag>N</notApplicableFlag>
<ownershipMoreThan5PercentOnBehalfOfAnotherPerson>The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

No one other person's interest in the securities reported herein is more than 5%.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>The Vanguard Group</reportingPersonName>
<signatureDetails>
<signature>Ashley Grim</signature>
<title>Head of Global Fund Administration</title>
<date>01/30/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
